Current status and future perspectives in the treatment of advanced testicular cancer

International Journal of Urology

Volumn 9, Issue 1, 2002, Pages 1-10

  Miki, Tsuneharu ^a   Nakao, Masahiro ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Advanced testicular cancer; Chemotherapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DACTINOMYCIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NEDAPLATIN; PACLITAXEL; PODOPHYLLIN; TENIPOSIDE; VINBLASTINE;

ADVANCED CANCER; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TESTIS CANCER; DISEASE COURSE; FORECASTING; MALE; PATHOLOGY; TESTIS TUMOR;

DISEASE PROGRESSION; FORECASTING; HUMAN; MALE; PROGNOSIS; TESTICULAR NEOPLASMS; HUMANS;

EID: 0036010607     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2002.00407.x     Document Type: Review

References (81)

1. Testicular cancer as a curable neoplasm: The Richard and Hinda Rosenthal Foundation award lecture
2. Treatment of testicular cancer: A new and improved model
3. High-dose cyclophosphamide (NSC-2726271) for the treatment of metastatic testicular neoplasms
4. Vinblastine in the management of testicular cancer
5. Phase II evaluation of bleomycin - A Southwest Oncology Group study
6. Continuous intravenous bleomycin (NSC-125066) and vinblastine (NSC-49842) in stage III testicular neoplasia
7. Vinblastine (NSC-49842) and bleomycin (NSC-125066) therapy for disseminated testicular cancer
8. Chemotherapy of germ cell tumors of the testis I. Induction of remissions with vinblastine, actinomycin D, and bleomycin
9. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode
10. Platinum compounds: A new class of potent antitumor agents
11. Diamminodichloroplatinum in the chemotherapy of testicular tumors
12. Germ cell tumors (II). VAB II in metastatic testicular cancer
13. VAB-3 combination chemotherapy of metastatic testicular cancer
14. VAB-4 combination chemotherapy in the treatment of metastatic testis tumors
15. VAB-6 combinaton chemotherapy without maintenance in treatment of disseminated cancer of the testis
16. VP-16-213 salvage therapy for refractory germinal neoplasms
17. The treatment of metastatic germ-cell testicular tumors with bleomycin, etoposide and cisplatin (BEP)
18. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide
19. Multivariate analysis of prognostic variables in patients with meta-static testicular cancer
20. Identification and management of poor risk patients with germ cell tumors: The Memorial Sloan-Kettering Cancer Center experience
21. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: Results from a European Organization for Research on Treatment of Cancer multiinstitutional phase III study
22. Prognostic factors for favorable outcome in disseminated germ cell tumors
23. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers
24. Randomized trial of etoposide and cisplatin versus etposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study
25. A randomized trial of etoposide+cisplatin versus vinblastine+bleomycin+cisplatin+cyclophosphamide+dactinomycin in patients with good-prognosis germ cell tumors
26. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma
27. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial
28. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Study Group
29. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ cell tumors: The Indiana University experience
30. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin
31. Four cycles of BEP versus four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group
32. Management of intermediate-prognosis germ-cell cancer: Results of a phase I/II study of taxol-BEP
33. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ cell tumors
34. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwestern Oncology Group Protocol
35. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study
36. Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors
37. Four cycles of BEP versus an alternating regimen of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group
38. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study
39. High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: The Memorial Sloan-Kettering experience
40. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis
41. Combination salvage chemotherapy using cisplatin and teniposide for patients with refractory germinal testicular tumors
42. Ifosfamide in refractory germ cell tumors
43. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival
44. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma
45. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumors
46. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin - A VihP regimen
47. Salvage chemotherapy with etoposide (E), ifosfamide (IFX), and cisplatin (P) (EIP) in refractory germ cell tumors (GCT)
48. High dose (HD) carboplatin (C), etoposide (E), and ifosfamide (I) with peripheral blood stem cell autotransplantation (PBSCT) in the first-line therapy for patients with poor-risk germ cell tumors (GCT): Pilot study of the Japan Blood Cell Transplantation Study Group
49. Long-term survivors after high dose chemotherapy with bone marrow rescue in refractory germ cell cancer
50. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study
51. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors. Treatment results and prognostic factors for survival and toxicity
52. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer
53. Testicular germ-cell cancer
54. High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: The French experience
55. High-dose chemotherapy with peripheral blood stem cell auto-transplantation for patients with poor-risk testicular germ cell tumors - Pilot study of the Japan Blood Cell Transplantation Study Group
56. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors
57. Paclitaxel in extensitvely pretreated nonseminomatous germ cell tumors
58. Phase II study of paclitaxel in patients with relapsed or cisplatin - Refractory testicular cancer
59. A phase II trial of paclitaxel in refractory germ cell tumors
60. Salvage treatment on germ-cell tumors using taxol, ifosfamide, cisplatin (TIP) followed by high-dose carboplatin, etoposide and thiotepa (HDCET): First result
61. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer
62. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients
63. Phase II study of docetaxel for recurrent or refractory germ cell cancer
64. Activity of gemcitabine in platinum-resistant ovarian germ cell cancer
65. Gemcitabine in patients with relapsed or cisplatin refractory testicular cancer
66. Phase II trial of gemcitabine in refractory germ cell tumors
67. Advantages in combination chemotherapy using the camptothecin analogue CPT-11 and cisplatinum analogues for human testicular cancer xerografts
68. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xerografts in nude mice
69. Salvage chemotherapy with CPT-11 and cisplatin for cisplatin refractory germ cell cancer
70. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience
71. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: A clinicopathological correlation
72. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction
73. Outcome analysis for patients with persistent nonseminomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections
74. Adjunct surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection
75. Surgery for a post-chemotherapy residual mass in seminoma
76. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer?
77. Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT)
78. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor; prediction of histology
79. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis
80. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumors
81. Treatment of patients with cisplatin-refractory testicular germ-cell cancer